GlaxoSmithKline Achieves Positive Results Blood Cancer Treatment Study
August 23 2019 - 2:43AM
Dow Jones News
By Oliver Griffin
GlaxoSmithKline PLC (GSK.LN) said Friday that headline results
from its DREAMM-2 study for treatment of multiple myeloma, a type
of blood cancer, were positive.
The pharmaceutical company said the two-arm study of its
treatment belantamab mafodotin met its primary objective and
demonstrated a clinically meaningful overall response rate.
Safety and tolerability was consistent with that observed in the
DREAMM-1 study, GlaxoSmithKline said.
Data from the DREAMM-2 study will be the basis for regulatory
filings starting later this year, the company said. Belantamab
mafodotin is on track for regulatory submission by the end of 2019,
it said.
Write to Oliver Griffin at oliver.griffin@dowjones.com;
@OliGGriffin
(END) Dow Jones Newswires
August 23, 2019 02:28 ET (06:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
